{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:49Z","timestamp":1789469149676,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006942","name":"Medical University of South Carolina","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006942","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Salvage chemotherapy and autologous stem cell transplantation (ASCT) offer the opportunity to cure eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL). Epigenetic alterations such as aberrant DNA methylation patterns have been linked to chemotherapy resistance in DLBCL. Oral Azacitadine (AZA) is a hypomethylating agent that inhibits DNA methyltransferase and has provided evidence of chemotherapy sensitization in DLBCL. In this phase I trial the safety and feasibility of two dose levels of AZA were investigated in combination with standard cytotoxic chemotherapy rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in relapsed DLBCL patients who were candidates for ASCT.<\/jats:p>","DOI":"10.1007\/s00277-026-07125-7","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T23:13:56Z","timestamp":1782083636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I study of oral azacitidine plus salvage chemotherapy in relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Brian","family":"Hess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina D.","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Hendrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Armeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Revuelta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanta","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Klingenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Cerchietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"7125_CR1","doi-asserted-by":"publisher","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333(23):1540-5. https:\/\/doi.org\/10.1056\/NEJM199512073332305","DOI":"10.1056\/NEJM199512073332305"},{"key":"7125_CR2","doi-asserted-by":"publisher","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Bri\u00e8re J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184-90. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618.\u00a0Erratum in: J Clin Oncol. 2012;30(15):1896","DOI":"10.1200\/JCO.2010.28.1618"},{"issue":"11","key":"7125_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","volume":"20","author":"M Hamadani","year":"2014","unstructured":"Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK (2014) Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl 20(11):1729\u20131736. https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.036","journal-title":"Biol Blood Marrow Transpl"},{"key":"7125_CR4","doi-asserted-by":"publisher","unstructured":"Mart\u00ednA, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, Garc\u00eda-Sanchez P, V\u00e1zquez L, Nistal S, Requena MJ, Donato EM, Gonz\u00e1lez JA, Le\u00f3n A, Ruiz C, Grande C, Gonz\u00e1lez-Barca E, Caballero MD, \/TAMO Cooperative Group) (2008) R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study. Haematologica 93(12):1829\u20131836. https:\/\/doi.org\/10.3324\/haematol.13440","DOI":"10.3324\/haematol.13440"},{"issue":"9","key":"7125_CR5","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","volume":"3","author":"T Clozel","year":"2013","unstructured":"Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden KL, Inghirami G, Leonard JP, Melnick A, Cerchietti L (2013) Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 3(9):1002\u20131019. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0117","journal-title":"Cancer Discov"},{"issue":"7","key":"7125_CR6","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/j.1349-7006.2010.01569.x","volume":"101","author":"K Amara","year":"2010","unstructured":"Amara K, Ziadi S, Hachana M, Soltani N, Korbi S, Trimeche M (2010) DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Sci 101(7):1722\u20131730. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01569.x","journal-title":"Cancer Sci"},{"issue":"22","key":"7125_CR7","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313\u20132323. https:\/\/doi.org\/10.1056\/NEJMoa0802885","journal-title":"N Engl J Med"},{"key":"7125_CR8","doi-asserted-by":"publisher","unstructured":"Kihslinger JE, Godley LA (2007) The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma 48(9):1676-95. https:\/\/doi.org\/10.1080\/10428190701493910","DOI":"10.1080\/10428190701493910"},{"key":"7125_CR9","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1038\/ncomms7921","volume":"6","author":"H Pan","year":"2015","unstructured":"Pan H, Jiang Y, Boi M, Tabb\u00f2 F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R, Melnick AM, Inghirami GG, Tam W, Elemento O (2015) Epigenomic evolution in diffuse large B-cell lymphomas. Nat Commun 6:6921. https:\/\/doi.org\/10.1038\/ncomms7921","journal-title":"Nat Commun"},{"issue":"6","key":"7125_CR10","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, Svekolkin V, Tikhonova E, Miheecheva N, Kuzkina N, Nos G, Tabbo F, Frenkel F, Ghione P, Tsiper M, Almog N, Fowler N, Melnick AM, Leonard JP, Inghirami G, Cerchietti L (2021) Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discov 11(6):1468\u20131489. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0839","journal-title":"Cancer Discov"},{"issue":"12","key":"7125_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood.2023021002","volume":"143","author":"L Cerchietti","year":"2024","unstructured":"Cerchietti L (2024) Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma. Blood 143(12):1101\u20131111. https:\/\/doi.org\/10.1182\/blood.2023021002","journal-title":"Blood"},{"issue":"8","key":"7125_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2021011679","volume":"139","author":"P Martin","year":"2022","unstructured":"Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones J, Drew J, Wu C, Mulvey E, Revuelta MV, Cerchietti L, Leonard JP (2022) Phase 1 study of oral azacitidine (ORAL AZACITADINE) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood 139(8):1147\u20131159. https:\/\/doi.org\/10.1182\/blood.2021011679","journal-title":"Blood"},{"key":"7125_CR13","doi-asserted-by":"publisher","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group, Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","DOI":"10.1200\/JCO.2013.54.8800"},{"issue":"4","key":"7125_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C (2017) Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14(4):417\u2013419. https:\/\/doi.org\/10.1038\/nmeth.4197","journal-title":"Nat Methods"},{"issue":"12","key":"7125_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"issue":"6","key":"7125_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, Osokin N, Kozlov I, Frenkel F, Gancharova O, Almog N, Tsiper M, Ataullakhanov R, Fowler N (2021) Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39(6):845\u2013865e7 Epub 2021 May 20. PMID: 34019806","journal-title":"Cancer Cell"},{"issue":"suppl 1","key":"7125_CR17","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1182\/blood-2022-169529","volume":"140","author":"N Di Siervi","year":"2022","unstructured":"Di Siervi N, Revuelta MV, Cacciapuoti MT, Zamponi N, Marullo R, Melnick A, Inghirami G, Cerchietti L (2022) FGFR1 Is a Novel Therapeutic Target in Relapsed\/Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL). Blood 140(suppl 1):1322","journal-title":"Blood"},{"issue":"9","key":"7125_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G, Diffuse Large B-C, Lymphoma (2021) N Engl J Med 384(9):842\u2013858. https:\/\/doi.org\/10.1056\/NEJMra2027612","journal-title":"N Engl J Med"},{"key":"7125_CR19","doi-asserted-by":"publisher","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620.\u00a0Erratum in: Blood. 2018;131(5):587\u2013588.\u00a0https:\/\/doi.org\/10.1182\/blood-2017-11-817775","DOI":"10.1182\/blood-2017-03-769620"},{"issue":"7","key":"7125_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Mu\u00f1oz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR (2022) All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 386(7):640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"key":"7125_CR21","doi-asserted-by":"publisher","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS (2022) Transform investigators. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399(10343):2294\u20132308. https:\/\/doi.org\/10.1016\/S0140-6736(22)00662-6. Erratum in: Lancet. 2022;400(10347):160.\u00a0 https:\/\/doi.org\/10.1016\/S0140-6736(22)01207-7","DOI":"10.1016\/S0140-6736(22)00662-6"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07125-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07125-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07125-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:49Z","timestamp":1789465369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07125-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7125"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07125-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8563481\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involved human participants and all procedures involved in this study were in accordance with the ethical standards of the Institutional Review Board of MUSC and Johns Hopkins University. Informed consent was obtained from all participants. The study followed the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethical standards and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.H. participated in advisory board with Incyte, Kite\/Gilead, ADC Therapeutics, Genmab and has Speaker\u2019s bureau with BMS. N.WJ. has Research funding from Astra Zeneca, Genetech, Merck. J.D. has consultancy with Jannsen Biotech, BMS, GSK and speaker\u2019s bureau with Janssen Biotech.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"405"}}